G. Chen

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

M. Kudo, R. Finn, B. Sangro, 2019, Annals of Oncology.

Updated efficacy and quality-of-life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/carboplatin in patients with EGFR-activating mutation-positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC).

Y. Wu, C. Zhou, X. Liu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma

M. Kudo, T. Yau, R. Finn, 2020 .

Orbital development in long-term survivors of retinoblastoma.

S. Kaste, C. Pratt, J. Fontanesi, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).

Y. Wu, Y. Luo, Q. Xiu, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients.

Rachel Liao, J. Yang, Y. Wu, 2007, Clinical oncology (Royal College of Radiologists (Great Britain)).

Reply to 'Concern on quality-of-life analysis in the OPTIMAL study' by Couraud et al.

Y. Wu, C. Zhou, G. Chen, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA4 IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)

C. Sternberg, M. Borre, M. Wongchenko, 2020 .

A phase II study (CTONG0803) of erlotinib as second-line treatment in advanced non-small cell lung cancer (NSCLC) patients (pts) with asymptomatic brain metastases (BM) after first-line chemotherapy (CT).

Y. Wu, C. Zhou, S. Lu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An observational study on the efficacy and safety of zoledronic acid (ZA) in patients with non-small cell lung cancer (NSCLC) patients with bone metastases with high urine n-telopeptide (uNTX) at diagnosis (C-TONG 0801).

Y. Wu, C. Zhou, M. Hou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Kidney Injury in Ordinary Adult Cases of Coronavirus Disease 2019

G. Chen, H. Yang, K. Pan, 2021 .